Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 74,992 shares, an increase of 173.1% from the May 14th total of 27,456 shares. Based on an average daily trading volume, of 283,609 shares, the short-interest ratio is currently 0.3 days. Approximately 0.0% of the shares of the company are short sold.
Analyst Upgrades and Downgrades
A number of brokerages have commented on SGIOY. The Goldman Sachs Group upgraded Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research report on Wednesday, April 8th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has an average rating of “Hold”.
Read Our Latest Report on Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. Unsponsored ADR Trading Down 0.2%
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. The firm had revenue of $881.71 million during the quarter, compared to analysts’ expectations of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. On average, equities research analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 EPS for the current year.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Featured Articles
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
